Daniel Cravo

This inventor holds 26 USPTO granted patents and 6 published patent applications, plus 13 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Poxel, Merck Patent Gmbh, Poxel S.a.s.. Active years: 2003-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Cravo. Retrieved from https://idiyas.com/inventor/daniel-cravo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 6)

% Patents Active = 57.7

CIPO Patents = 13

EPO Patents = 20 (Patent Applications = 18)

Average Co-Inventor Count = 3.5

ph-index = 7

Forward Citations = 114(Granted Patents)

Location History:

Sartrouville, FR (2003 - 2015)
Montesson, FR (2012 - 2018)

Company Filing History:

National Institute of Health and Medical Research

patents

5. 2 out of 5,383

Centre National De La Recherche Scientifique

Ens-Ecole Normale Superieure De Lyon

University Claude Bernard - Lyon 1

Merck Patent Gesellschaft

patents

12. 1 out of 1,248

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

Areas of Expertise:

Hepatitis B

AMPK Activators

Diabetes Treatment

Thienopyridone

Triazine Derivatives

Ischemia

Glucokinase Activators

Enantiomeric Separation

Bicyclic Guanidine

Biguanide Derivatives

Therapeutic Uses

Pharmaceutical Compositions

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10071108 - Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection (2018-09-11),

2. 9895380 - Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection (2018-02-20),

3. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),

4. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),

5. 9271984 - Treatment of type 1 diabetes (2016-03-01),

6. 9035048 - Tetrahydrotriazine compounds for treating diseases associated with AMPK activity (2015-05-19),

7. 8980828 - Combination of insulin with triazine derivatives and its use for treating diabetes (2015-03-17),

8. 8937066 - Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases (2015-01-20),

9. 8791115 - Combination of triazine derivatives and insulin sensitisers (2014-07-29),

10. 8742103 - Separation of triazine derivatives enantiomers using tartaric acid (2014-06-03),

11. 8742102 - Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization (2014-06-03),

12. 8674097 - Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase (2014-03-18),

13. 8604202 - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators (2013-12-10),

14. 8592370 - Combination of insulin with triazine derivatives (2013-11-26),

15. 8563729 - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators (2013-10-22),

Title: **The Innovative Journey of Daniel Cravo: Pioneering Treatments for Hepatitis B**

Introduction

Daniel Cravo, based in Sartrouville, France, is an accomplished inventor with a remarkable portfolio of 26 patents. His innovative work primarily focuses on the development of methods and pharmaceutical compositions aimed at treating Hepatitis B virus infections, showcasing his commitment to addressing significant health challenges.

Latest Patents

Cravo's latest patents revolve around novel approaches to combat Hepatitis B. Specifically, his inventions delve into methods and pharmaceutical compositions utilizing farnesoid X receptor (FXR) agonists. These advancements are designed to treat individuals afflicted with Hepatitis B virus infection, highlighting the potential for enhanced therapeutic strategies in the medical field.

Career Highlights

Throughout his career, Daniel Cravo has gained valuable experience working with notable companies such as Poxel and Merck Patent GmbH. His involvement in these organizations has allowed him to refine his expertise in pharmaceutical innovations, driving research and development forward in the industry.

Collaborations

Cravo has collaborated with distinguished colleagues, including Didier Mesangeau and Sophie Hallakou-Bozec. These partnerships underscore the collaborative nature of pharmaceutical research, where shared insights and expertise contribute significantly to advancements in treatment options.

Conclusion

Daniel Cravo's contributions to the field of medicine, particularly in the treatment of Hepatitis B, demonstrate his ingenuity and dedication as an inventor. With a robust patent portfolio and significant collaborations, he continues to make strides in developing innovative solutions that hold the promise of improving patient outcomes. His work serves as an inspiration for future inventors and researchers aiming to make a positive impact in healthcare.

Profile summary based on public USPTO records.